FILIP1L

Summary

FILIP1L (filamin A interacting protein 1 like, HGNC:24589) is a protein-coding gene on chromosome 3q12.1, encoding Filamin A-interacting protein 1-like (Q4L180). Acts as a regulator of the antiangiogenic activity on endothelial cells.

Predicted to be involved in protein localization to actin cytoskeleton. Predicted to act upstream of or within several processes, including hindgut development; proteasomal protein catabolic process; and protein secretion. Predicted to be located in cytoplasm; membrane; and nucleus. Predicted to be active in actin cytoskeleton and centrosome.

Source: NCBI Gene 11259 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 11 total
• MANE Select transcript: NM_001387850

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24589
Approved symbol	FILIP1L
Name	filamin A interacting protein 1 like
Location	3q12.1
Locus type	gene with protein product
Status	Approved
Aliases	DOC-1, GIP130
Ensembl gene	ENSG00000168386
Ensembl biotype	protein_coding
OMIM	612993
Entrez	11259

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000331335, ENST00000354552, ENST00000383694, ENST00000398326, ENST00000468533, ENST00000471562, ENST00000476723, ENST00000477258, ENST00000487087, ENST00000495625

RefSeq mRNA: 8 — MANE Select: NM_001387850 NM_001042459, NM_001282793, NM_001282794, NM_001370247, NM_001387850, NM_001387852, NM_014890, NM_182909

CCDS: CCDS43117, CCDS43118, CCDS43119, CCDS63700, CCDS74969, CCDS93331

Canonical transcript exons

ENST00000477258 — 6 exons

Exon	Start	End
ENSE00001822355	99828811	99830605
ENSE00002255350	99930769	99931030
ENSE00002273323	99929856	99930029
ENSE00002292471	99924230	99924408
ENSE00003519650	99848295	99851070
ENSE00003920901	100114053	100114501

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 99.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 38.9712 / max 6072.6070, expressed in 1572 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43473	24.7151	1544
43474	5.8787	661
43472	3.6736	796
43460	3.0016	288
43480	0.3346	30
43463	0.2910	84
43459	0.2412	74
43481	0.2385	31
43462	0.2271	63
43461	0.2046	62

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
saphenous vein	UBERON:0007318	99.48	gold quality
cauda epididymis	UBERON:0004360	99.19	gold quality
blood vessel layer	UBERON:0004797	98.76	gold quality
vena cava	UBERON:0004087	98.68	gold quality
urethra	UBERON:0000057	98.59	gold quality
descending thoracic aorta	UBERON:0002345	98.36	gold quality
superficial temporal artery	UBERON:0001614	98.27	gold quality
thoracic aorta	UBERON:0001515	98.06	gold quality
ascending aorta	UBERON:0001496	98.00	gold quality
right coronary artery	UBERON:0001625	97.99	gold quality
aorta	UBERON:0000947	97.67	gold quality
popliteal artery	UBERON:0002250	97.38	gold quality
tibial artery	UBERON:0007610	97.36	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.08	gold quality
gall bladder	UBERON:0002110	96.99	gold quality
colonic epithelium	UBERON:0000397	96.53	gold quality
triceps brachii	UBERON:0001509	96.22	gold quality
calcaneal tendon	UBERON:0003701	96.22	gold quality
left coronary artery	UBERON:0001626	96.12	gold quality
coronary artery	UBERON:0001621	96.04	gold quality
biceps brachii	UBERON:0001507	95.84	gold quality
sperm	CL:0000019	95.83	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.73	gold quality
diaphragm	UBERON:0001103	95.70	gold quality
lower esophagus	UBERON:0013473	95.66	gold quality
gluteal muscle	UBERON:0002000	95.59	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	95.59	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.49	gold quality
smooth muscle tissue	UBERON:0001135	95.43	gold quality
mucosa of stomach	UBERON:0001199	95.43	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	29.76
E-CURD-46	yes	24.42
E-MTAB-8410	yes	19.86
E-CURD-112	yes	13.28
E-MTAB-10553	yes	7.13
E-HCAD-9	yes	5.18
E-GEOD-130148	yes	4.84
E-MTAB-6678	no	3.73
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREB1

miRNA regulators (miRDB)

47 targeting FILIP1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-3171	99.49	69.06	776
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-8064	99.45	66.92	875
HSA-MIR-6882-5P	99.35	71.13	1206

Literature-anchored findings (GeneRIF, showing 12)

• DOC1 might play a role in mediating some of the effects of EMAP-II on endothelial cells (PMID:15935955)
• these findings suggest that downregulation of FILIP1L associated with DNA methylation is related with the invasive phenotype in ovarian cancer and that modulation of FILIP1L expression has the potential to be a target for ovarian cancer therapy. (PMID:21693594)
• a novel function for FILIP-1L and a pathway for Hsf1 degradation through the ubiquitin-proteasome system. (PMID:21784850)
• GPBP directs myofibril formation through interaction with intracellular downstream effector 130-kDa GPBP-interacting protein (PMID:21832087)
• In addition, eight genes classified as ‘second tier’ hits in the original study (PAX7, THADA, COL8A1/FILIP1L, DCAF4L2, GADD45G, NTN1, RBFOX3 and FOXE1) showed evidence of linkage and association in this replication sample. (PMID:23512105)
• these findings suggest that FILIP1L reduces beta-catenin levels, which may lead to the transcriptional downregulation of WNT target genes such as MMPs, resulting in inhibition of metastasis (PMID:24327474)
• down-regulation of FILIP1L associated with DNA methylation is related with the invasive phenotype in various cancers. (PMID:24340050)
• FILIP1L inhibits progression in colorectal cancer by inhibiting tumor cell proliferation and angiogenesis. (PMID:27750216)
• Studies have shown that FILIP1L expression is related with inhibition of metastases and chemoresistance of ovarian neoplasm, which is associated with downregulation of EMT through beta-catenin degradation. FILIP1L expression correlates with significantly improved overall survival. (PMID:27776341)
• FILIP1L Loss Is a Driver of Aggressive Mucinous Colorectal Adenocarcinoma and Mediates Cytokinesis Defects through PFDN1. (PMID:34417201)
• FILIP1L-mediated cell apoptosis, epithelial-mesenchymal transition and extracellular matrix synthesis aggravate posterior capsular opacification. (PMID:34666037)
• Long-chain noncoding RNA LINC01569 upregulates filamin A-interacting protein 1-like to prevent metastasis of triple-negative breast cancer via sponging miR-300. (PMID:37955081)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Filip1l	ENSMUSG00000043336
rattus_norvegicus	Filip1l	ENSRNOG00000001645
caenorhabditis_elegans		WBGENE00016792

Paralogs (3): FILIP1 (ENSG00000118407), CTTNBP2NL (ENSG00000143079), LUZP1 (ENSG00000169641)

Protein

Protein identifiers

Filamin A-interacting protein 1-like — Q4L180 (reviewed: Q4L180)

Alternative names: 130 kDa GPBP-interacting protein, 90 kDa GPBP-interacting protein, Protein down-regulated in ovarian cancer 1

All UniProt accessions (3): Q4L180, C9JYJ6, H7C4M0

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a regulator of the antiangiogenic activity on endothelial cells. When overexpressed in endothelial cells, leads to inhibition of cell proliferation and migration and an increase in apoptosis. Inhibits melanoma growth When expressed in tumor-associated vasculature.

Subcellular location. Cytoplasm. Membrane. Nucleus.

Tissue specificity. Expressed in endothelial cells, colon and colon cancers. In the colon, expressed in the vasculature and muscularis mucosa. In colon cancer, strongly expressed in tumor stroma and the vasculature (at protein level). Expressed in ovarian epithelial cells. Down-regulated in ovarian cancer.

Induction. Up-regulated in endothelial cells with the angiogenesis inhibitors endostatin and fumagillin. By endothelial monocyte-activating polypeptide II in endothelial cells.

Similarity. Belongs to the FILIP1 family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q4L180-1	1, a, d	yes
Q4L180-2	2, b, c
Q4L180-3	3
Q4L180-4	4
Q4L180-5	5
Q4L180-6	6
Q4L180-7	7

RefSeq proteins (8): NP_001035924, NP_001269722, NP_001269723, NP_001357176, NP_001374779, NP_001374781, NP_055705, NP_878913 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019131	Cortactin-binding_p2_N	Domain
IPR050719	Cortactin-Actin_Reg	Family

Pfam: PF09727

UniProt features (22 total): splice variant 7, sequence conflict 5, modified residue 4, sequence variant 2, chain 1, region of interest 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q4L180-F1	68.64	0.39

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 791, 986, 994, 1052

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 264 (showing top): MODULE_52, GOBP_PROTEIN_LOCALIZATION_TO_CYTOSKELETON, HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, FOSTER_TOLERANT_MACROPHAGE_UP, MAINA_VHL_TARGETS_UP, INGRAM_SHH_TARGETS_UP, RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN, MODULE_99, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, GENTILE_UV_HIGH_DOSE_DN, COATES_MACROPHAGE_M1_VS_M2_UP, WANG_CISPLATIN_RESPONSE_AND_XPC_DN, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE

GO Biological Process (1): protein localization to actin cytoskeleton (GO:1903119)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), actin cytoskeleton (GO:0015629), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein localization to cytoskeleton	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoskeleton	1

Protein interactions and networks

STRING

1239 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FILIP1L	SLC16A8	O95907	668
FILIP1L	RAD51B	O15315	607
FILIP1L	B3GLCT	Q6Y288	581
FILIP1L	ADAMTS9	Q9P2N4	566
FILIP1L	ERVW-1	Q9UQF0	550
FILIP1L	COL8A1	P27658	505
FILIP1L	H3BT92	H3BT92	472
FILIP1L	IER3	P46695	459
FILIP1L	FLNC	Q14315	448
FILIP1L	DDR1	Q08345	443
FILIP1L	TGFBR1	P36897	439
FILIP1L	CMSS1	Q9BQ75	435
FILIP1L	HMCN1	Q96RW7	416
FILIP1L	SIRAL2	Q9NWS6	406
FILIP1L	FRK	P42685	401

IntAct

8 interactions, top by confidence:

A	B	Type	Score
FILIP1L	PDIA3	psi-mi:“MI:0915”(physical association)	0.400
FILIP1L	PCNA	psi-mi:“MI:0915”(physical association)	0.370
BVLF1	VWA8	psi-mi:“MI:0914”(association)	0.350
SOX4	SEC16A	psi-mi:“MI:2364”(proximity)	0.270
SP7	IGF2BP3	psi-mi:“MI:2364”(proximity)	0.270
FILIP1L	nusB	psi-mi:“MI:0915”(physical association)	0.000
FILIP1L	grpE	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (21): FILIP1L (Affinity Capture-MS), FILIP1L (Affinity Capture-RNA), SMTN (Two-hybrid), FILIP1L (Two-hybrid), FILIP1L (Proximity Label-MS), FILIP1L (Proximity Label-MS), FILIP1L (Proximity Label-MS), FILIP1L (Proximity Label-MS), FILIP1L (Affinity Capture-MS), FILIP1L (Affinity Capture-MS), FILIP1L (Proximity Label-MS), FILIP1L (Cross-Linking-MS (XL-MS)), FILIP1L (Cross-Linking-MS (XL-MS)), SMC1A (Cross-Linking-MS (XL-MS)), FILIP1L (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0MZ66, A0MZ67, A6PWD2, A7MD70, B3DLE8, B9EKI3, F7DP49, O35550, O35551, O45420, P82094, Q05D60, Q08DR9, Q15276, Q28IH8, Q3KR99, Q3UIJ9, Q4L180, Q4R7H3, Q4V7C8, Q53EZ4, Q5BIX7, Q5R923, Q5RA03, Q5RI56, Q5U3Z6, Q6NRC9, Q6NRW2, Q6P0R8, Q6P402, Q6P6L0, Q7YS99, Q7Z7B0, Q861Q8, Q8BT07, Q8BVC4, Q8K2Q9, Q8K3K8, Q8K4T4, Q8R5M4

Diamond homologs: A0M8S4, A0M8T5, A1X157, B9EJA2, Q00PJ1, Q07DV1, Q07DW4, Q07DX4, Q07DY4, Q07DZ5, Q07E15, Q07E28, Q07E41, Q09YG9, Q09YI1, Q09YJ3, Q09YK4, Q09YM8, Q108T9, Q2IBA2, Q2IBB2, Q2IBD4, Q2IBE6, Q2IBF7, Q2IBF8, Q2QL82, Q2QLA2, Q2QLB3, Q2QLF8, Q2QLG9, Q4L180, Q5RDH2, Q6P6L0, Q8SX68, Q8WZ74, Q99LJ0, Q9P2B4, A3KNA5, Q7Z7B0, Q8K4T4

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
FILIP1L	“down-regulates quantity by destabilization”	FLNC	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	11
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4860 predictions. Top by Δscore:

Variant	Effect	Δscore
3:100051302:GAGTA:G	donor_gain	1.0000
3:100051304:GTA:G	donor_gain	1.0000
3:99986345:CAT:C	acceptor_gain	1.0000
3:99986347:T:TC	acceptor_gain	1.0000
3:100003230:CA:C	acceptor_gain	0.9900
3:100003231:A:C	acceptor_gain	0.9900
3:100004501:GAT:G	donor_gain	0.9900
3:100010130:GGTAA:G	acceptor_gain	0.9900
3:100011374:T:TA	donor_gain	0.9900
3:100011375:A:AA	donor_gain	0.9900
3:100019783:GGA:G	donor_gain	0.9900
3:100019784:GAG:G	donor_gain	0.9900
3:100019786:G:GG	donor_gain	0.9900
3:100033382:G:GT	donor_gain	0.9900
3:100051305:T:TA	donor_gain	0.9900
3:100051306:A:AA	donor_gain	0.9900
3:100109212:A:AG	acceptor_gain	0.9900
3:99836675:A:G	donor_gain	0.9900
3:99841060:G:GG	donor_gain	0.9900
3:99851067:TAAT:T	acceptor_gain	0.9900
3:99851068:AATC:A	acceptor_loss	0.9900
3:99851069:ATCT:A	acceptor_loss	0.9900
3:99851070:TC:T	acceptor_loss	0.9900
3:99851071:C:CC	acceptor_gain	0.9900
3:99851071:C:T	acceptor_loss	0.9900
3:99851072:T:G	acceptor_loss	0.9900
3:99876375:GGAA:G	donor_gain	0.9900
3:99878677:GGC:G	donor_gain	0.9900
3:99882237:C:A	donor_gain	0.9900
3:99924405:CCAA:C	acceptor_gain	0.9900

AlphaMissense

7899 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:99848485:A:G	I1064T	0.998
3:99848491:A:G	I1062T	0.998
3:99848926:A:T	L917H	0.998
3:99848965:A:G	I904T	0.998
3:99848965:A:T	I904K	0.998
3:99848833:A:G	I948T	0.997
3:99848839:A:G	I946T	0.997
3:99848926:A:G	L917P	0.997
3:99848491:A:C	I1062S	0.996
3:99848833:A:T	I948N	0.996
3:99848932:G:T	A915D	0.996
3:99848959:A:T	V906D	0.996
3:99848485:A:C	I1064S	0.995
3:99848485:A:T	I1064N	0.995
3:99848920:A:G	I919T	0.995
3:99848833:A:C	I948S	0.994
3:99848920:A:C	I919S	0.994
3:99848965:A:C	I904R	0.994
3:99849376:A:G	L767P	0.994
3:99848880:A:C	S932R	0.993
3:99848880:A:T	S932R	0.993
3:99848882:T:G	S932R	0.993
3:99848349:G:C	S1109R	0.992
3:99848349:G:T	S1109R	0.992
3:99848351:T:G	S1109R	0.992
3:99848839:A:T	I946K	0.991
3:99848959:A:G	V906A	0.991
3:99850198:A:G	L493P	0.991
3:99850972:A:G	L235P	0.991
3:99848491:A:T	I1062N	0.990

dbSNP variants (sampled 300 via entrez): RS1000004816 (3:99904708 A>G), RS1000048422 (3:100027567 C>T), RS1000049619 (3:99833364 C>T), RS1000053667 (3:99889444 A>C), RS1000054268 (3:99890725 G>A,T), RS1000075081 (3:100093441 T>A,C), RS1000098534 (3:99944169 C>T), RS1000108258 (3:99882293 T>C), RS1000112198 (3:99988877 T>G), RS1000115249 (3:99897848 T>G), RS1000129984 (3:99944413 C>A,T), RS1000136078 (3:99853285 A>G), RS1000144746 (3:100080095 T>C), RS1000149869 (3:99833887 T>A), RS1000150773 (3:100007368 A>G)

Disease associations

OMIM: gene MIM:612993 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001884_18	Age-related macular degeneration	4.000000e-13
GCST002115_7	Axial length	5.000000e-11
GCST004988_436	Breast cancer	5.000000e-10
GCST009462_49	Optic disc size	2.000000e-08
GCST010002_434	Refractive error	5.000000e-25
GCST012228_65	Waist-hip index	3.000000e-08
GCST012228_67	Waist-hip index	3.000000e-10
GCST012230_264	Waist-to-hip ratio adjusted for BMI	4.000000e-08
GCST012230_265	Waist-to-hip ratio adjusted for BMI	5.000000e-08
GCST012230_267	Waist-to-hip ratio adjusted for BMI	5.000000e-10
GCST012231_187	A body shape index	1.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005318	axial length measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

78 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, decreases expression, increases expression	6
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, affects expression	4
Valproic Acid	increases expression, affects expression, decreases expression	4
sodium arsenite	decreases expression	3
Air Pollutants	affects cotreatment, increases abundance, increases expression, decreases expression	3
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
Particulate Matter	increases abundance, decreases expression	3
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Benzo(a)pyrene	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	increases expression	2
Cyclosporine	decreases expression	2
ethylbenzene	increases expression	1
methylmercuric chloride	increases expression	1
methyleugenol	increases expression	1
alpha-pinene	increases abundance, affects cotreatment, increases expression	1
bisphenol A	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	decreases expression	1
arsenite	affects expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	increases abundance, increases expression	1
2-xylene	increases expression	1
benzo(e)pyrene	increases methylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	decreases expression, affects cotreatment	1
aflatoxin B2	increases methylation	1
nickel sulfate	decreases expression	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.